Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TELA Bio (TELA) Change in Receivables (2018 - 2025)

TELA Bio has reported Change in Receivables over the past 8 years, most recently at -$932000.0 for Q4 2025.

  • Quarterly results put Change in Receivables at -$932000.0 for Q4 2025, up 5.19% from a year ago — trailing twelve months through Dec 2025 was $110000.0 (down 85.56% YoY), and the annual figure for FY2025 was $110000.0, down 85.56%.
  • Change in Receivables for Q4 2025 was -$932000.0 at TELA Bio, down from $107000.0 in the prior quarter.
  • Over the last five years, Change in Receivables for TELA hit a ceiling of $2.0 million in Q3 2024 and a floor of -$983000.0 in Q4 2024.
  • Median Change in Receivables over the past 5 years was $319500.0 (2023), compared with a mean of $395200.0.
  • Biggest five-year swings in Change in Receivables: soared 1502.44% in 2021 and later plummeted 161.36% in 2024.
  • TELA Bio's Change in Receivables stood at $657000.0 in 2021, then soared by 35.46% to $890000.0 in 2022, then surged by 80.0% to $1.6 million in 2023, then plummeted by 161.36% to -$983000.0 in 2024, then grew by 5.19% to -$932000.0 in 2025.
  • The last three reported values for Change in Receivables were -$932000.0 (Q4 2025), $107000.0 (Q3 2025), and $533000.0 (Q2 2025) per Business Quant data.